The ONE Program: Continued Innovation and Expansion Oliver Frenzel, PharmD, RPh, MPH

This roundtable presentation will provide a brief overview of the ONE Program which includes the number of screenings that have been conducted since inception, the number of participating pharmacies, and patient-focused interventions that are provided by the pharmacist. In addition, we will discuss the attitudes and perceptions of ONE Program pharmacists that have successfully incorporated the opioid-risk screening process, as well as barriers and facilitators. Finally, we will discuss the patient-care expansion activities the ONE Program has facilitated in opioid harm prevention efforts and opportunities for expansion into their practices.

The ONE Program: Continued Innovation and Expansion



- The ONE Program (Opioid and Naloxone Education) is a pharmacy-centered opioid risk screening process that provides pharmacists with resources needed to screen patients receiving an opioid prescription. The screening tool assists the pharmacist in identifying patients at risk for opioid use disorder (OUD) and/or accidental opioid overdose.
 Screening results enable pharmacists to deliver individualized education and opioidharm-reduction strategies for patients at the highest risk for negative outcomes.
- In North Dakota, 75 Pharmacies are actively screening patients with the ONE Program; with over 25,000 documented opioid risk screenings since the inception of the program in 2018. In addition, 97.4% of patients screened as 'high-risk' for opioid use disorder (OUD) and/or accidental opioid overdose have received critical interventions by pharmacists.
- The ONE Program screening process provides a high level of utility in opioid harm reduction activities. An evaluation was conducted to assess the benefits of the ONE Program; 100% of pharmacists indicated that the screening process had improved communication and opportunities for interventions with patients. In addition, nearly all pharmacists agreed that the screening process and patient consultation are not timeconsuming (~5min for each encounter) and are easy to incorporate into existing workflow.
- Over the past 2 years, the ONE Program has sought opportunities to expand the reach of opioid harm reduction activities. The ONE screening has since been used by Home Health and Hospice organizations, Community Paramedics, Local Public Health Units conducting home visits, and incarcerated populations. This expansion focuses on opioid harm reduction; and also proper medication disposal, medication adherence, and safe medication storage.
- 'Be the ONE' is an outreach initiative focusing on College/University populations.
 Naloxone rescue kits are now available at 11 NDUS Institutions. Over 400 University
 System students, instructors, and staff have been educated on the use and availability of the rescue kits.
- Replication of the ONE Program is occurring in pharmacy networks located in Minnesota and West Virginia.



ONE Program Patient Intake Form

Patient Name: _	Date of Birth:	

Circle patient's birth gender: MALE FEMALE

YES NO Has the patient taken this or other opioid medications in the last 60 days? Examples: Duragesic® (fentanyl), Oxycontin® (oxycodone), Vicodin® (hydrocodone), morphine

	(oxycodone), v	reddin (nydrocodone), morphine			
			Yes	No	
Opioid Misuse Risk Assessment	Family history of substance abuse				
	Alcohol				
	Illegal drugs				
	Prescription me	dication misuse			
	Personal history of substance abuse				
	Alcohol				
	Illegal drugs				
	Prescription medication misuse				
	Age between 16 - 45 years				
	History of preadolescent sexual abuse				
	Psychological disease				
)		tion deficit disorder (ADD), obsessive compulsive disorder (OCD), blar disorder, schizophrenia			
	Depression				
Accidental Overdose Risk Assessment	Circle the age the	e patient is in: Less than 45 45-64 Greater than 64			
	Medical history: Circle all those which apply to the patient.				
	asthma depre	ession anxiety COPD/emphysema sleep apnea liver disease kidney	disease		
k A	While using this medication is there a chance the patient may consume any of the following?				
Ris]		Medication used to treat anxiety			
se]	Examples: Xanax [®] (alprazolam), Ativan [®] (lorazepam), Valium [®] (diazepam) Klonopin [®] (clonazepam)				
op.	YES NO Medication used to treat depression				
ver	YES NO Medication known as a muscle relaxer				
10	Examples: Flexeril® (cyclobenzaprine), Skelaxin® (metaxalone)				
nta		Medication used to aid in sleep (prescription or over the counter)			
deı	YES NO YES NO	Cough or cold medication			
cci	YES NO YES NO				
A	1E5 NU	Are you currently taking other opioid medications? Examples: Duragesic (fentanyl), Oxycontin (oxycodone), Vicodin (hydrocodone), morphine			